More on CHGCY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.40 |
|
|||
| Open | $21.17 | ||||
| 52 Wk High | $74.63 | ||||
| 52 Wk Low | $56.80 | ||||
| Day High | $21.61 | ||||
| Day Low | $20.67 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 219,494 | ||||
- FDA grants priority review to Genentech's Enspryng for rare disease MOGAD
- U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
- Roche gets FDA clearance for two new laboratory analytical units
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
- /C O R R E C T I O N -- Roche/
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
- Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
- Roche gets CE mark for blood test detecting Alzheimer's gene variant
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
Entities mentioned with CHGCY
- FDA | View Related Stories »
- Industrial Production | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Definitive Agreement | View Related Stories »
- AdCom | View Related Stories »
- Deutsche Bank | View Related Stories »
- Earnings | View Related Stories »
- Show More...
